Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzopril and Apatinib Maintenance in Platinum-Resistant Ovarian Cancer
NCT06102707Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Nov 2023
- Primary completion
- Nov 2025
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of Rivoceranib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Disease progression free survival at 36 months. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT06102707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06102707.